Trials / Completed
CompletedNCT00769119
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Bronchiectasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Bronchiectasis (Brx) and if so how it compares to placebo (a substance which does not have any action).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD9668 | 2 x 30 mg, oral tablet, twice daily for 28 days |
| DRUG | Placebo | 2 x Matched placebo, oral tablet, twice daily for 28 days |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2008-10-08
- Last updated
- 2012-08-20
- Results posted
- 2012-07-25
Locations
9 sites across 2 countries: Canada, United Kingdom
Source: ClinicalTrials.gov record NCT00769119. Inclusion in this directory is not an endorsement.